Oxidative-Stress in Human Diseases—3rd Edition

A special issue of Antioxidants (ISSN 2076-3921). This special issue belongs to the section "Health Outcomes of Antioxidants and Oxidative Stress".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 579

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Natural Products and Nutrition, MIGAL—Galilee Research Institute, Kiryat Shmona 11016, Israel
2. Faculty of Sciences, Tel Hai Academic College, Qiryat Shemona 12208, Israel
Interests: natural compounds; analytical chemistry; metabolomics; oxidative stress; atherosclerosis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Oxidative stress (OS) is essential in the pathogenesis of human chronic diseases such as cardiovascular and kidney diseases, diabetes, neurodegenerative disorders, cancer, inflammation-related diseases, and aging. OS is a condition characterized by an imbalance between the production and accumulation of oxygen and nitrogen reactive species (ROS/RNS) in cells and tissues, and it occurs when the generation of these compounds exceeds the ability of the biological system to neutralize them.

ROS/RNS, such as superoxide (O2•−), hydrogen peroxide (H2O2), hydroxyl radical (HO), nitrogen oxide (NO), peroxynitrite (ONOO), and hypochlorous acid (HOCl), are all products of normal metabolic pathways in humans; their production may increase as a result of influential external factors, such as pollution, cigarette smoke, or internally, as a result of impaired intracellular metabolism. Long-term exposure to increased levels of ROS/RNS can cause structural defects of lipids, proteins, DNA, and RNA, as well as the functional alteration of several enzymes and cellular structures, leading to an increase in OS and pathogenesis.

We invite you to share your latest original and innovative research findings or review articles in this upcoming Special Issue, “Oxidative-Stress in Human Diseases—3rd Edition”. We welcome clinical and pre-clinical studies on the relationship between OS and human diseases, novel diagnosis methods and mechanisms, as well as approaches for preventing and treating diseases related to OS.

Dr. Soliman Khatib
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oxidative stress
  • ROS/RNS
  • human diseases
  • antioxidants
  • OS biomarkers

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

19 pages, 1487 KiB  
Article
Catalase, Glutathione Peroxidase, and Peroxiredoxin 2 in Erythrocyte Cytosol and Membrane in Hereditary Spherocytosis, Sickle Cell Disease, and β-Thalassemia
by Daniela Melo, Fátima Ferreira, Maria José Teles, Graça Porto, Susana Coimbra, Susana Rocha and Alice Santos-Silva
Antioxidants 2024, 13(6), 629; https://doi.org/10.3390/antiox13060629 - 22 May 2024
Viewed by 367
Abstract
Catalase (CAT), glutathione peroxidase (GPx), and peroxiredoxin 2 (Prx2) can counteract the deleterious effects of oxidative stress (OS). Their binding to the red blood cell (RBC) membrane has been reported in non-immune hemolytic anemias (NIHAs). Our aim was to evaluate the relationships between [...] Read more.
Catalase (CAT), glutathione peroxidase (GPx), and peroxiredoxin 2 (Prx2) can counteract the deleterious effects of oxidative stress (OS). Their binding to the red blood cell (RBC) membrane has been reported in non-immune hemolytic anemias (NIHAs). Our aim was to evaluate the relationships between CAT, GPx, and Prx2, focusing on their role at the RBC membrane, in hereditary spherocytosis (HS), sickle cell disease (SCD), β-thalassemia (β-thal), and healthy individuals. The studies were performed in plasma and in the RBC cytosol and membrane, evaluating OS biomarkers and the enzymatic activities and/or the amounts of CAT, GPx, and Prx2. The binding of the enzymes to the membrane appears to be the primary protective mechanism against oxidative membrane injuries in healthy RBCs. In HS (unsplenectomized) and β-thal, translocation from the cytosol to the membrane of CAT and Prx2, respectively, was observed, probably to counteract lipid peroxidation. RBCs from splenectomized HS patients showed the highest membrane-bound hemoglobin, CAT, and GPx amounts in the membrane. SCD patients presented the lowest amount of enzyme linkage, possibly due to structural changes induced by sickle hemoglobin. The OS-induced changes and antioxidant response were different between the studied NIHAs and may contribute to the different clinical patterns in these patients. Full article
(This article belongs to the Special Issue Oxidative-Stress in Human Diseases—3rd Edition)
Show Figures

Figure 1

Back to TopTop